小儿III型血脂异常：一例消失性高脂血症病例。
Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia.
作者信息
Sarwal Gautamn, Al-Sarraf Ahmad, Frohlich Jiri
机构信息
University of British Columbia, Vancouver, Canada.
出版信息
BMJ Case Rep. 2012 Nov 1;2012:bcr2012007579. doi: 10.1136/bcr-2012-007579.
Abstract
An 11-year-old girl presented with palmar and tuberoeruptive xanthomas, and elevated triglycerides and total cholesterol levels. She had an apolipoprotein E2/E2 genotype. A diagnosis of type III dyslipidaemia was made and the patient started on niacin, fenofibrate and salmon oil. At age 18, her lipid levels were well controlled with fenofibrate once weekly. At age 21, the fenofibrate was discontinued and her lipid profile has been normal for the last 4 years. This case history may be consistent with a transient dyslipidaemia.
摘要
一名11岁女孩出现掌部和结节性疹性黄瘤，甘油三酯和总胆固醇水平升高。她具有载脂蛋白E2/E2基因型。诊断为III型血脂异常，患者开始服用烟酸、非诺贝特和鱼油。18岁时，她的血脂水平通过每周一次的非诺贝特得到良好控制。21岁时，停用了非诺贝特，在过去4年里她的血脂谱一直正常。该病例史可能与短暂性血脂异常相符。
相似文献
1
Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia.
BMJ Case Rep. 2012 Nov 1;2012:bcr2012007579. doi: 10.1136/bcr-2012-007579.
2
Apolipoprotein E2 (Arg-136-->Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia.
Eur J Clin Invest. 1996 Jan;26(1):13-23. doi: 10.1046/j.1365-2362.1996.83232.x.
3
Severe Combined Dyslipidemia With a Complex Genetic Basis.
J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619877050. doi: 10.1177/2324709619877050.
4
Dysbetalipoproteinaemia--clinical and pathophysiological features.
S Afr Med J. 2002 Nov;92(11):892-7.
5
Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia.
Atherosclerosis. 1996 Aug 2;124(2):183-9. doi: 10.1016/0021-9150(96)05819-4.
6
Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment.
Atherosclerosis. 1985 Nov;57(2-3):249-66. doi: 10.1016/0021-9150(85)90038-3.
7
Treatment of type III hyperlipoproteinemia.
Am Heart J. 1999 Jul;138(1 Pt 1):17-8. doi: 10.1016/s0002-8703(99)70239-5.
8
Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.
Circ Cardiovasc Genet. 2010 Oct;3(5):462-7. doi: 10.1161/CIRCGENETICS.110.950667. Epub 2010 Aug 21.
9
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
Am J Cardiol. 2011 Mar 1;107(5):793-6. doi: 10.1016/j.amjcard.2010.10.063. Epub 2011 Jan 19.
10
Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
Eur J Clin Chem Clin Biochem. 1995 Nov;33(11):799-804. doi: 10.1515/cclm.1995.33.11.799.
引用本文的文献
1
Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences.
Mol Autism. 2020 Jul 27;11(1):62. doi: 10.1186/s13229-020-00358-x.
本文引用的文献
1
Case series of type III hyperlipoproteinemia in children.
BMJ Case Rep. 2011 Jun 9;2011:bcr0220113895. doi: 10.1136/bcr.02.2011.3895.
2
Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study.
Lipids Health Dis. 2011 Sep 11;10:157. doi: 10.1186/1476-511X-10-157.
3
Transient dyslipidemia mimicking the plasma lipid profile of Tangier disease in a diabetic patient with gram negative sepsis.
Ann Clin Lab Sci. 2011 Spring;41(2):150-3.
4
Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.
Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000.
5
Aripiprazole in schizophrenia and schizoaffective disorder: A review.
Clin Ther. 2010;32 Suppl 1:S3-20. doi: 10.1016/j.clinthera.2010.01.021.
6
Familial dysbetalipoproteinemia: a potentially fatal disorder.
J Coll Physicians Surg Pak. 2008 Aug;18(8):506-8.
7
Hypertriglyceridemia: its etiology, effects and treatment.
CMAJ. 2007 Apr 10;176(8):1113-20. doi: 10.1503/cmaj.060963.
8
Dysbetalipoproteinaemia--clinical and pathophysiological features.
S Afr Med J. 2002 Nov;92(11):892-7.
9
Acquired lipoprotein lipase deficiency associated with chronic urticaria. A new etiology for type I hyperlipoproteinemia.
Eur J Endocrinol. 1999 Nov;141(5):502-5. doi: 10.1530/eje.0.1410502.
10
Hypertriglyceridemia as a cardiovascular risk factor.
Am J Cardiol. 1998 Feb 26;81(4A):7B-12B. doi: 10.1016/s0002-9149(98)00031-9.
Zotero 插件